BCRX Q3 Performance and Discussion*For a copy of Q3 earnings transcript, click here. To be directed to BCRX full page with reports and more, click here. Robust Orladeyo Launch Continues; Blockbuster … [Read more...] about BCRX Q3 Results & Discussion
Why We Dont Like Aurinia At $3B
Co authored by Zion MillerIntroduction: In response to recent backlash over bearish remarks on popular companies, we have decided to frame our stance in concise articles, starting with Aurina … [Read more...] about Why We Dont Like Aurinia At $3B
Gritstone Bio (GRTS) Makes History in a Historically Hopeless Setting
As mentioned in our last report, Gritstone Bio (GRTS) initially applied its next-generation heterologous (virus/sa-mRNA) vaccine technology to fight cancer. The thesis articulated by the founding … [Read more...] about Gritstone Bio (GRTS) Makes History in a Historically Hopeless Setting
BioCryst Pharmaceuticals (BCRX) 2Q21 Earnings Highlights
This morning our baby BCRX reported stellar 2Q21 earnings beating our internal expectations as well as those set by Wall Street. Key takeaways: Orladeyo launch maintained momentum and trajectory from … [Read more...] about BioCryst Pharmaceuticals (BCRX) 2Q21 Earnings Highlights
Embarrassment of T Cell Riches
GRTS: Embarrassment of T Cell Riches It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our … [Read more...] about Embarrassment of T Cell Riches
GRTS Goldman Sachs Investor Conference 2021 Transcript
Participants: Salveen Richter (SR) Andrew Allen (AA) SR: Hi good morning everyone my name is Salveen Richter, a Senior Biotech Analyst at Goldman Sachs thank you for joining us. We are … [Read more...] about GRTS Goldman Sachs Investor Conference 2021 Transcript
Gene Therapy Exciting, But Early
Gene therapy involves inserting genetic material into cells to prevent, cure, or correct a disease caused by genetic abnormalities whereas gene editing involves making actual changes to the genetic … [Read more...] about Gene Therapy Exciting, But Early
Kintara Therapeutcis (NASDAQ: KTRA)….
Since our last article discussing Kintara Therapeutics (NASDAQ: KTRA) underappreciated value proposition to investors, CEO Saiid Zarrabian has solidified the company’s position for growth in 2021 and … [Read more...] about Kintara Therapeutcis (NASDAQ: KTRA)….
First Quarter 2021 Earnings Highlights: BCRX and GRTS
BioCryst Pharmaceuticals (Nasdaq: BCRX)Rating: OutperformPT= $20-$30 (in 3-12 months)In the over 30 years since its inception, this was by far the most historic and monumental earnings call for BCRX. … [Read more...] about First Quarter 2021 Earnings Highlights: BCRX and GRTS
GRTS Trades at Enterprise Value With a Potential Covid-19 Variant Answer
With over 500K Americans dead since the outbreak of the COVID-19 pandemic and only modest easing of restrictions after a year of lockdowns despite a nationwide vaccine rollout, people are looking for … [Read more...] about GRTS Trades at Enterprise Value With a Potential Covid-19 Variant Answer
You must be logged in to post a comment.